Sandhill Research LLC

1. Moderna TX, Inc. $9,851,155 3,786 payments
2. Bavarian Nordic A/S $2,130,329 124 payments
3. AstraZeneca Pharmaceuticals LP $1,793,767 27 payments
4. Eli Lilly and Company $1,730,081 26 payments
5. GlaxoSmithKline, LLC. $1,266,025 172 payments
6. AbbVie, Inc. $1,141,669 339 payments
7. Novavax Inc $795,542 99 payments
8. Pfizer Inc. $742,684 180 payments
9. Eisai Inc. $661,261 19 payments
10. Genentech, Inc. $499,149 82 payments

1. A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 $2,316,193 1,143 payments
2. A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405, Multivalent Candidate Vaccines to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 49 Years of Age and 60 to 80 Years of Age $1,463,921 26 payments
3. ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 $1,385,740 55 payments
4. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $960,121 42 payments
5. A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis $826,686 124 payments
6. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $661,261 19 payments
7. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $625,413 853 payments
8. A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event $599,476 2 payments
9. A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age $595,754 9 payments
10. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $584,089 106 payments

1. Patient care $74,842 29 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.